Global Pulmonary Arterial Hypertension (PAH) Industry Key Trends, Growth Drivers, Regional Analysis and 2015-2019 Forecast Research Report at OrbisResearch.com

Scope of the Report
The report titled “Global PAH Market: Trends and Opportunities (2015-2019)”, analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/185293 .

The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.

The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.

Purchase a copy of Global Pulmonary Arterial Hypertension (PAH) Market visit @ http://www.orbisresearch.com/contact/purchase/185293  For more information contact [email protected]   .

Company Coverage
Actelion Limited
United Therapeutics Limited
SteadyMed Limited

PAH Drug Mechanism
Endothelin Receptor Antagonists (ERA) 
PDE 5 Inhibitors 
Prostacyclins
sGC Stimulator

Executive Summary
Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.

In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion develop the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.

Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.

Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-pulmonary-arterial-hypertension-pah-market-trends-and-opportunities-2015-2019  .

Some points from TOC:

1. Executive Summary

2. Pulmonary Arterial Hypertension (PAH): An Introduction
2.1 Definition of PAH 
2.2 Classification of PAH 
2.3 Causes of PAH 
2.4 Who gets PAH? 
2.5 How Serious is PAH? 
2.6 Symptoms of PAH 
2.7 Diagnosis of PAH 
2.8 Treatment of PAH 
2.8.1 Medications 
2.8.2 Surgery 
2.8.3 Lifestyle Changes 
2.9 How does it affect?

For any enquires before buying, connect with us @ [email protected]

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas – 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +9164101019

Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research

Follow us on Twitter: https://twitter.com/orbisresearch

Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115